title: [Pregnancy and malignant diseases part I--general principles].
abstract: The occurrence of a neoplastic disease during pregnancy is rare, from 0.02 to 0.1% or one in 1000-1500 pregnancies. Nevertheless, such an occurrence has a remarkable social and medical effect, because malignancies are the leading cause of disabilities in and death of women at a reproductive age. It is expected that these cases will become more frequent due to the increasing age of delivering women and the spreading of new reproductive technologies. The treatment of pregnant women with malignancy is in conformity with the accepted standards for the respective localization in general. The individualization of the treatment is connected predominantly to preserving the reproductive ability of women and avoiding the damage of the fetus and newborn. Surgery and chemotherapy after the first trimester are relatively safe for the fetus. Radiotherapy, especially in the pelvic region, has heavy and lethal aftereffects and is incompatible with the preservation of the pregnancy. The final decision for the term and the way of delivery demands a multidisciplinary team including obstetricians-gynecologists and neonatologists. The time necessary for the consultations and the choice of management is justifiable and does not worsen the prognosis. For the prevention of early and long-term problems connected with prematurity it is necessary to extend the pregnancy until 35-37 g.w.
authors.forename: P
authors.initials: P
authors.lastname: Kosyova
authors.forename: V
authors.initials: V
authors.lastname: Zlatkov
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D004358:Drug Therapy; D005260:Female; D006801:Humans; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D011878:Radiotherapy
chemical_list: D000970:Antineoplastic Agents